Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: A 12-week randomized study

Allergy and Asthma Proceedings

Volumn 25, Issue 6, 2004, Pages 445-448

  Riccioni, Graziano ^a,c   Della Vecchia, R ^b   Di Ilio, C ^a   D'Orazio, N ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale SS Annunziata   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR STIMULATING AGENT; MONTELUKAST; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EMOTION; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; MALE; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY; SYMPTOM;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; QUINOLINES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 13544252692     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. National Institute of Health (NIH). National Asthma Education Prevention Program. Expert panel report II: Guidelines for the diagnosis and management of asthma. NIH Publication No. 97-4051, NIH, Bethesda, MD, 1997.
2. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax 47:76-83, 1992.
3. Marks GB, Dunn SM, and Woolcock AJ. A scale for measurement of quality of life in adults with asthma. J Clin Epidemiol 45:461-472, 1992.
4. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 115: 1265-1270, 1999.
5. Ducharme F. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ 326:621-626, 2003.
6. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 17:96-101, 2001.
7. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 31:845-851, 2001.
8. National Hearth, Lung, and Blood Institute. National Asthma Education and Prevention Program. NAEPP expert panel report guidelines for the diagnosis and management of asthma. 2002 NIH Publication No. 02-5075, National Hearth, Lung, and Blood Institute, Bethesda, MD, 2002.
9. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 161:S73-S76, 2000.
10. Wenzel SE. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Am J Respir Crit Care Med 158: 1699-1701, 1998.
11. Ind PW. Inhaled corticosteroids versus antileukotrienes: A literature review on the clinical effects. Allergy 54:43-46, 1999.
12. Riccioni G, Ballone E, Sensi S, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopathol Pharmacol 15:149-155, 2002.
13. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 14:1038-1043, 1999.
14. Nathan RA, Bernstein GA, Bielory L, et al. Zafirukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 102:935-942, 1998.
15. Bousquet J, Duchateau J, Pignat JC, et al. Improvement in quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 98:309-316, 1996.
16. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 152:1107-1136, 1999.
17. Weinberg EG, and Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 11:49-55, 2000.
18. Riccioni G, Santilli F, D'Orazio N, et al. The role of antileukotrienes in the treatment of asthma. Int J Immunopathol Pharmacol 15:171-182, 2002.
19. Reiss TF, Chervinsky RJ, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 158:1213-1220, 1998.
20. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mold-to moderate asthma. A randomized, double blind placebo controlled trial. Ann Intern Med 126:177-183, 1997.
21. Fish GE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. The Zafirlukast Trialist Group. Clin Ther 19:675-690, 1997.